Biosimilars and Follow-on Biologics.
- Resource Type
- Article
- Authors
- MCSHEA, MICHAEL; BORNS, MARK; POLLOM, ROY DANIEL
- Source
- Pharmacy Times. Nov2016, Vol. 82 Issue 11, p72-76. 4p.
- Subject
- *BIOLOGICALS
*RECOMBINANT human insulin
*PREVENTIVE medicine
*DRUG prescribing
*PHARMACISTS
*SAFETY
- Language
- ISSN
- 0003-0627
The article focuses on the differences between biosimilars and follow-on biologics (FOBs). Topics include the production of biologics in living cells or organisms, use in the prevention and treatment of a disease, and first approved biologic product Humulin R recombinant human insulin from Eli Lilly and Co. Information regarding the need for pharmacists to be experts on FOBs to educate health professionals about safe prescribing and use is also provided.